Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 31;67(6):965-970.
doi: 10.1093/cid/ciy297.

Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia

David P Serota  1 , Eli S Rosenberg  2 , Annie M Lockard  3 , Charlotte-Paige M Rolle  4   5 , Nicole Luisi  3 , Scott Cutro  6 , Carlos Del Rio  1   5 , Aaron J Siegler  3 , Travis H Sanchez  3 , Patrick S Sullivan  3 , Colleen F Kelley  1
Affiliations

Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia

David P Serota et al. Clin Infect Dis. .

Abstract

Human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) has high biomedical efficacy; however, awareness, access, uptake, and persistence on therapy remain low among black men who have sex with men (BMSM), who are at highest risk of HIV in the United States. To date, discussions of "PrEP failure" have focused on one typology: rare, documented HIV acquisitions among PrEP users with adequate serum drug levels (ie, biomedical failure). In our cohort of HIV-negative young BMSM in Atlanta, Georgia, we continue to observe a high HIV incidence (6.2% annually at interim analysis) despite access to free PrEP services. Among 14 seroconversions, all were offered PrEP before acquiring HIV. Among these participants, we identified 4 additional typologies of PrEP failure that expand beyond biomedical failure: low PrEP adherence, PrEP discontinuation, PrEP contemplation without initiation, and PrEP refusal. We describe the 5 typologies and suggest interventions to improve PrEP effectiveness among those at highest risk.

Trial registration: ClinicalTrials.gov NCT02503618.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A, Timelines in 14 participants (A–N) with human immunodeficiency virus (HIV) seroconversion occurring after preexposure prophylaxis (PrEP) was offered in the EleMENt cohort. B, Proposed framework of PrEP failure typologies, beginning with biomedical failures (case A) and expanding to include low PrEP adherence (case B), PrEP discontinuation (cases C and D), PrEP contemplation (cases E–I), and PrEP refusal (cases J–N). Systems failures are represented as a ring joining the other 4 typologies, given the cross-cutting nature of this barrier to PrEP effectiveness.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med 2017; 376:501–2. - PubMed
    1. Markowitz M, Grossman H, Anderson PL, et al. . Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis. J Acquir Immune Defic Syndr 2017; 76:e104–6. - PMC - PubMed
    1. Hoornenborg E, Prins M, Achterbergh RCA, et al. ; Amsterdam PrEP project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM) Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV 2017; 4:e522–8. - PubMed
    1. Hoots BE, Finlayson T, Nerlander L, Paz-Bailey G; National HIV Behavioral Surveillance Study Group Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men-20 US cities, 2014. Clin Infect Dis 2016; 63:672–7. - PMC - PubMed
    1. Hess K, Hu X, Lansky A, et al. . Estimating the lifetime risk of a diagnosis of HIV infection in the United States. Presented at: Conference on Retroviruses and Opportunistic Infections; 22–25 February2016; Boston, Massachusetts.

Publication types

MeSH terms

Substances

Associated data